Surface Oncology Management to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day
24 Abril 2019 - 8:00AM
Surface Oncology (NASDAQ:SURF), a clinical-stage
immuno-oncology company developing next-generation immunotherapies
that target the tumor microenvironment, today announced that Jeff
Goater, chief executive officer, will be participating and
presenting a corporate update at the Solebury Trout Class of 2018
Biotech IPOs Investor Day, hosted together with Davis Polk and BMO
Capital Markets. The company will be closing the NASDAQ market as
part of the conference on Thursday, April 25th.
Presentation details: Event:
Solebury Trout Class of 2018 Biotech IPOs Investor Day
Date: Friday, April 26th Time:
9:30 AM ETLocation: Davis Polk Offices, New York,
NY
A live and archived webcast of the presentation can
be accessed by visiting the Investors page of the website at
https://investors.surfaceoncology.com/news-events/events.
About Surface Oncology:
Surface Oncology is an immuno-oncology company developing
next-generation antibody therapies focused on the tumor
microenvironment with lead programs targeting CD73, CD39, IL-27 and
CD47. Surface’s novel cancer immunotherapies are designed to
achieve a clinically meaningful and sustained anti-tumor response
and may be used alone or in combination with other therapies. The
company has a pipeline of seven novel immunotherapies and a
strategic collaboration with Novartis focused on NZV930
(CD73) and potentially one additional undisclosed program. For more
information, please visit www.surfaceoncology.com.
Contacts: Seth Lewis
slewis@surfaceoncology.com 617-665-5031
Krystle Gibbs Ten Bridge Communications
krystle@tenbridgecommunications.com 508-479-6358
Surface Oncology (NASDAQ:SURF)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Surface Oncology (NASDAQ:SURF)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024